This article was originally published in The Gray Sheet
Stock swap acquisition of arterial access site closure device maker Perclose, valued at $644 mil., is completed, Abbott announces Nov. 19. The deal was announced in July (1"The Gray Sheet" July 12, p. 3)
You may also be interested in...
Abbott's July 8 acquisition of Perclose in a stock swap valued at about $680 mil. portends the firm's long-term strategy to expand its interventional cardiology presence at a tempered pace.
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.